Interactions with the Public

Amgen is committed to providing robust and meaningful information to health care providers, decision makers, and patients not only regarding Amgen products, but also regarding the disease states our products are intended to treat. For these communications to have the best chance at contributing to positive patient outcomes, it is necessary that these disease communications are transparent, ethical, and non-promotional in nature. To this end, Amgen requires that all communications with members of the healthcare community receive review and approval from legal, regulatory and medical experts.


Section 3 of Chapter 2 of the Amgen Blue Book

As of August 4, 2023